Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 3Pain, Postoperative 2Neoplasms 2Head and Neck Neoplasms 2Wounds and Injuries 1Supratentorial Neoplasms 1Sigmoidal Tumour 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain, Intractable 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Nalbuphine Allergy 1Immune System Suppression 1Ileus 1Diverticulosis, Colonic 1Diverticulitis, Colonic 1Constipation 1Colonic Neoplasms 1Chronic Pain 1Cancer Pain 1Breast Neoplasms 1Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction 1Agnosia 1

Interventions

Nalbuphine 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Nalbuphine Allergy × Morphine × Clear all
NCT05073744 2022-12-29

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Zhongda Hospital

Phase 4 Unknown
316 enrolled

Nalbuphine Allergy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡